Get the Stockscreener App
8.74
2.22%
0.19
Pre-market:
8.58
-0.16
-1.83%
Exagen Inc stock is traded at $8.74, with a volume of 341.39K.
It is up +2.22% in the last 24 hours and up +14.25% over the past month.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
See More
Previous Close:
$8.55
Open:
$8.44
24h Volume:
341.39K
Relative Volume:
1.11
Market Cap:
$211.73M
Revenue:
$68.38M
Net Income/Loss:
$-20.17M
P/E Ratio:
-9.888
EPS:
-0.8839
Net Cash Flow:
$-14.13M
1W Performance:
+11.05%
1M Performance:
+14.25%
6M Performance:
+218.98%
1Y Performance:
-18.92%
1-Day Range:
$8.28
$8.86
1-Week Range:
$7.87
$8.88
52-Week Range:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
8.74 | 211.73M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Eastern Progress
Exagen (XGN) Receives a Buy from Roth MKM - The Globe and Mail
EXAGEN INC. Q1 REVENUE USD 17.306 MILLION VS. IBES ESTIMATE USD 16.4 MILLION - Moomoo
Exagen Inc.(NasdaqGM: XGN) dropped from S&P Global BMI Index - marketscreener.com
Exagen Stock Price Forecast. Should You Buy XGN? - StockInvest.us
Exagen Inc.Common Stock (NQ: XGN - The Chronicle-Journal
Exagen Q2FY26 Results: Revenue hits record $19.9 million, EBITDA nears breakeven - scanx.trade
Full Transcript: Exagen Q2 2026 Earnings Call - Benzinga
XGN Looks 113.8% Overvalued on GF Value™ - GuruFocus
Have Insiders Sold Exagen Shares Recently? - simplywall.st
XGN Q2 2026 Earnings: Loss Narrows on Strong EPS BeatEarnings Stability Report - dars.gov.et
Tax-driven stock sale and ESPP buy for Exagen (XGN) CFO - Stock Titan
XGN Q2 2026 Earnings: Loss Narrows to -$0.13, Delivering 32.26% EPS Surprise, Yet Shares Ease 1.73% - dars.gov.et
XGN | Exagen Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Exagen Inc. (XGN) Stock Price & News - Syfe
Exagen (XGN) director grant corrects prior option total - Stock Titan
Exagen (NASDAQ: XGN) grants director options at $4.31 strike - Stock Titan
Exagen (NASDAQ: XGN) grants Paul Kim 37,500 options at $4.31 - Stock Titan
Exagen Q2 2026 slides: record revenue, stock surges 36% By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN - MarketBeat
GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN - MarketBeat
XGN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentEarnings Acceleration Picks - vinanet.vn
XGN Q2 2026 Earnings: Narrower -$0.13 Loss Beats Estimates; Shares Slip 2.66%Retail Earnings Report - vinanet.vn
XGN Q2 2026 Earnings: Narrower-than-Expected Loss Surprises Positively, Yet Shares Slip 1.99%Management Tone Analysis - vinanet.vn
Exagen at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - AOL.com
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results - webull.com
Agenus: Q2 Earnings Snapshot - aol.com
Exagen Inc. (XGN) Climbs 4.25% to $6.87, Holding Above Key SupportTPO Profile - dars.gov.et
Exagen (XGN) Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 4.25%Mid-Term Outlook - dars.gov.et
Exzeo: Q2 Earnings Snapshot - AOL.com
Xenon Pharmaceuticals: Q2 Earnings Snapshot - AOL.com
Exagen Q2 2026 Earnings: Record Revenue and Reduced EBITDA Loss - sekbernews.id
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN) - The Globe and Mail
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution - Yahoo Finance
XGN Maintains Buy Rating -- Price Target Raised to $10.00 by TD Cowen - GuruFocus
XGN Reiterates by B. Riley Securities -- Price Target Raised to $12 - GuruFocus
Exagen Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-08-05 - Seeking Alpha
XGN Maintained by BTIG -- Price Target Raised to $9.00 - GuruFocus
Insiders At Exagen Sold US$680k Of Stock Potentially Indicating Weakness - Moomoo
B. Riley Adjusts Price Target on Exagen to $12 From $8, Maintains Buy Rating - marketscreener.com
BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Reve - GuruFocus
Exagen: The Path To Profitability Just Became More Credible (NASDAQ:XGN) - Seeking Alpha
Exagen revenue reaches record level in Q2 2026 as test volume and ASP climb, lifts full year outlook - Traders Union
Exagen Inc. Stock 12‑Month Price Target Raised to $8.71, Implies 86% Upside - TradingView
Exagen Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability - Yahoo Finance
Exagen Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20% - Investing.com Nigeria
Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue H - GuruFocus
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):